Tokyo, Japan

Ayako Mikami

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Taisho Pharmaceutical Co., Ltd.. Active years: 2008-2012.

USPTO Granted Patents = 2 

Average Co-Inventor Count = 3.4

ph-index = 1

Forward Citations = 12(Granted Patents)


Location History:

  • Tokyo, JP (2008)
  • Toshima-ku, JP (2012)

Company Filing History:


Years Active: 2008-2012

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ayako Mikami: Innovator in Pharmaceutical Compounds

Introduction

Ayako Mikami is a prominent inventor based in Tokyo, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that exhibit beneficial health effects. With a total of 2 patents to her name, her work is recognized for its innovative approach to addressing health issues.

Latest Patents

Mikami's latest patents include a compound that has excellent 11β-HSD1 inhibitory activity. This invention provides a novel compound that is effective in reducing triglyceride levels in the liver and lowering blood glucose levels. The compound is represented by a specific formula that includes various substituents, showcasing her expertise in medicinal chemistry.

Career Highlights

Ayako Mikami is currently associated with Taisho Pharmaceutical Co., Ltd., where she continues to advance her research and development efforts. Her work is pivotal in creating effective pharmaceutical solutions that can improve health outcomes for patients.

Collaborations

Mikami collaborates with talented colleagues such as Ryo Suzuki and Hiroaki Tanaka. Together, they contribute to the innovative environment at Taisho Pharmaceutical Co., Ltd., fostering advancements in pharmaceutical research.

Conclusion

Ayako Mikami's contributions to the field of pharmaceuticals through her innovative patents highlight her role as a leading inventor. Her work not only showcases her expertise but also has the potential to significantly impact health and wellness.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…